By Rishika Sadam

MUMBAI, Sept 25 (Reuters) - Eli Lilly ( LLY ) plans to

bring its experimental oral weight-loss drug orforglipron to

India as it sees market potential in the world's most populous

nation, a senior executive said on Thursday.

"I do think there is promise for products like that

(orforpligron) in India, if it does get approved," Winselow

Tucker, Lilly India's president said at an event in Mumbai.

Tucker, however, did not indicate when Lilly plans to launch

the drug.

The drugmaker has bid for approval for the experimental pill

after latest clinical data showed it lowered average blood sugar

and weight in a head-to-head trial of adults with type-2

diabetes more effectively than rival Novo Nordisk's

older GLP-1 pill Rybelsus.

Lilly's orforglipron is designed to mimic the

appetite-suppressing GLP-1 hormone targeted by the company's

blockbuster injection tirzepatide, sold under the brand names

Mounjaro and Zepbound.